MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Educational Programs for Patients with Parkinson disease and Deep Brain Stimulation: Scoping Riview

    M. Petralito, C. Tedesco, F. Fanari, G. Pucciarelli, R. Caruso (Roma, Italy)

    Objective: Map the literature on educational programs for patients with Parkinson's disease and Deep Brain Stimulation, analysing the characteristics that the programmes have and the…
  • 2024 International Congress

    Clinical and Radiologic Predictors for a Longer Benefit of Cerebrospinal Fluid Decompression in Normal Pressure Hydrocephalus

    J. Lee, M. Sunwoo (Seongnam-si, Republic of Korea)

    Objective: To explore the clinical characteristics and predictors for longer benefit of gait after cerebrospinal fluid (CSF) decompression test in patients with normal pressure hydrocephalus…
  • 2024 International Congress

    Real-World Retrospective Safety Analysis in Patients Treated With OnabotulinumtoxinA for Multiple Therapeutic Indications Over Repeat Treatment Periods

    G. Forde, A. Patel, K. Martinez, A. Mayadev, B. Brucker, T. Brown, Z. Ayyoub, R. Singh, M. Nelson, A. Ukah, I. Yushmanova, S. Battucci, K. Becker Ifantides, C. Rhyne (New Hyde Park, USA)

    Objective: To evaluate the real-world safety of onabotulinumtoxinA (onabotA) use over repeat treatment periods (TPs) in patients (pts) with concomitant multiple therapeutic indications. Background: In…
  • 2024 International Congress

    Antibody-mediated movement disorders: a single-centre retrospective study

    J. Moura, S. Costa, I. Carrilho, S. Figueiroa, P. Carneiro, E. Neves, J. Damásio, E. Santos, R. Samões (Porto, Portugal)

    Objective: This study aims to evaluate the clinical spectrum of antibody-associated movement disorders from a single centre. Background: There is an increasing recognition of movement…
  • 2024 International Congress

    Botulinum Toxin A Usage in Movement Disorder Division: A Retrospective Chart Review

    S. Shaikh, R. Figari Jordan (Charlottesville, USA)

    Objective: To evaluate the cost-effectiveness of Botulinum Toxin A in our movement disorder division. Background: Botulinum Toxin A is an FDA-approved treatment for various medical…
  • 2024 International Congress

    Understanding Patient and Care Partner Educational Preferences in Atypical Parkinsonism

    M. Ivancic, M. Comeau, R. Mahabir, C. Malburg, J. Shurer, K. Woods, E. Zivin, CY. Lin (Chapel Hill, USA)

    Objective: To discern preferences for education and community connection among people affected by progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), or multiple system atrophy (MSA).…
  • 2024 International Congress

    Initiating a Hybrid-Modality International Movement Disorders Fellowship: A Collaborative Effort Among Latin American Countries

    P. Salles, S. Peña, S. Silva, R. Jauregui, P. Saffie, P. Chaná-Cuevas (Santiago de Chile, Chile)

    Objective: To describe a hibrid modality with high-quality, well-structured and overseeded education program. Background: In the field of movement disorders, specialized centers have emerged as…
  • 2024 International Congress

    Maintaining Isometric Contraction in Parkinson’s Disease: Effect of PD-Medication on EMG Amplitude

    B. Afsharipour, F. Roy, M. Schindle, F. Ba, M. Gorassini, T. Sankar (Edmonton, Canada)

    Objective: To quantify muscle activity changes in PD with dopaminergic medication. Background: Parkinson's disease (PD) is characterized by motor symptoms that improve with dopaminergic medication.…
  • 2024 International Congress

    Effects of Osteopathic Manipulative Treatment (OMT) on Lower Extremity Muscle Characteristics in Parkinson’s Disease (PD) Patients

    R. Radigan, A. Finkelstein, M. Mehra, P. Bhushan, T. Lombardo, S. Yao (Old Westbury, USA)

    Objective: To define the mechanism of Osteopathic Manipulative Treatment (OMT) in decreasing symptomology and improving gait in Parkinson’s Disease (PD) patients. Background: A key symptom…
  • 2024 International Congress

    GAD-Positive Versus GAD-Negative Stiff Person Syndrome: A Retrospective Study

    W. Khan, M. Hamed, H. Ooi, H. Sarva, M. Salgado, D. Victor (Doha, Qatar)

    Objective: Delineate demographic and clinical differences between GAD-65-antibody positive (seropositive) and negative (seronegative) SPS. Background: Elevated Glutamic Acid Decarboxylase 65 antibody (GAD-65 Ab) titers are…
  • « Previous Page
  • 1
  • …
  • 265
  • 266
  • 267
  • 268
  • 269
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley